Due to the high incidence of hyperlipidemia secondary to lorlatinib, do you recommend empiric statin therapy to all patients without known contraindications upon initiation of lorlatinib?

I do not empirically start statin therapy. However, I will check lipid and triglyceride levels prior to initiation of lorlatinib and periodically (every 3-6 months) thereafter. I will initiate or change statins in patients where we see a rise in lipids and triglycerides. I will aim for a level that ...